FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

wasnington,	D.C.	20549	

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHA
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ABBV]									Check a	tionship of Reporting all applicable) Director		ng Pei	10% C	wner
(Last)	(Fi	,	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/04/2018										Office belov	cer (give title ow)		Other (specify below)	
(Street) NORTH CHICAG			50064 Zip)		4. If	Ame	endment,	ndment, Date of Original Filed (Month/Day/Year)							ine) X					
		Tabl	e I - Nor	n-Deriv	ative	Se	curitie	s Acc	quired,	Disp	osed o	f, or	Bene	efici	ally O	wne	ed			
1. Title of Security (Instr. 3) 2. Trans Date (Month/					Execution (Control of the Control of		. Deemed ecution Date, any onth/Day/Year)		Transaction Disposed Code (Instr. 5)		ities Acquired (A) d Of (D) (Instr. 3,			ind S	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(4	A) or D)	Price	, ті	ransaction(s) nstr. 3 and 4)				(1130.4)
Common stock, \$0.01 par value				05/0	05/04/2018				A ⁽¹⁾		1,899)	Α	\$0	(1)	34,335			D	
Common stock, \$0.01 par value														350(2)			I	By Wife		
		Та	ble II - [sed of, onvertib				y Owr	ned				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (Execution Date, if any (Month/Day/Year)				Date,	4. Transaction Code (Instr. 8)		Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe		ount		rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(: (Instr. 4)	, [Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	of Sha	res						

Explanation of Responses:

- 1. These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
- $2. \ The \ reporting \ person \ disclaims \ beneficial \ ownership \ of \ all \ securities \ held \ by \ his \ wife.$

Steven L. Scrogham, attorneyin-fact for Glenn F. Tilton 05/07/2018

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.